NASDAQ:ENTX - Entera Bio Stock Price, News & Analysis

+0.08 (+2.97 %)
(As of 08/26/2019 06:00 AM ET)
Today's Range
Now: $2.77
50-Day Range
MA: $3.08
52-Week Range
Now: $2.77
Volume500 shs
Average Volume17,286 shs
Market Capitalization$31.66 million
P/E RatioN/A
Dividend YieldN/A
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:ENTX



Sales & Book Value

Annual Sales$500,000.00
Book Value$0.57 per share


Net Income$-10,300,000.00


Market Cap$31.66 million
Next Earnings Date1/28/2020 (Estimated)
OptionableNot Optionable

Receive ENTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.

Entera Bio (NASDAQ:ENTX) Frequently Asked Questions

What is Entera Bio's stock symbol?

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

How were Entera Bio's earnings last quarter?

Entera Bio Ltd (NASDAQ:ENTX) posted its quarterly earnings results on Tuesday, August, 20th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.16. The firm had revenue of ($0.07) million for the quarter. View Entera Bio's Earnings History.

When is Entera Bio's next earnings date?

Entera Bio is scheduled to release their next quarterly earnings announcement on Tuesday, January 28th 2020. View Earnings Estimates for Entera Bio.

What price target have analysts set for ENTX?

1 equities research analysts have issued 12 month price objectives for Entera Bio's stock. Their forecasts range from $8.00 to $8.00. On average, they expect Entera Bio's stock price to reach $8.00 in the next year. This suggests a possible upside of 188.8% from the stock's current price. View Analyst Price Targets for Entera Bio.

What is the consensus analysts' recommendation for Entera Bio?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Entera Bio.

Has Entera Bio been receiving favorable news coverage?

Media stories about ENTX stock have trended positive recently, according to InfoTrie. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Entera Bio earned a news impact score of 2.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for Entera Bio.

Are investors shorting Entera Bio?

Entera Bio saw a decline in short interest during the month of July. As of July 31st, there was short interest totalling 5,600 shares, a decline of 13.8% from the June 30th total of 6,500 shares. Based on an average trading volume of 12,800 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the shares of the company are short sold. View Entera Bio's Current Options Chain.

Who are some of Entera Bio's key competitors?

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Supernus Pharmaceuticals (SUPN), BorgWarner (BWA), Canopy Growth (CGC), Honeywell International (HON), Baozun (BZUN), Cara Therapeutics (CARA), Celgene (CELG), Galmed Pharmaceuticals (GLMD), Alphabet (GOOG) and Kamada (KMDA).

Who are Entera Bio's key executives?

Entera Bio's management team includes the folowing people:
  • Dr. Phillip Schwartz Ph.D., CEO & Director (Age 57)
  • Dr. Hillel Galitzer, Chief Operating Officer (Age 41)
  • Dr. Roger J. Garceau, Chief Devel. Advisor & Director (Age 65)
  • Dr. Arthur C. Santora II, Chief Medical Officer

When did Entera Bio IPO?

(ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

Who are Entera Bio's major shareholders?

Entera Bio's stock is owned by many different of retail and institutional investors. Top institutional investors include DLD Asset Management LP (3.23%).

Which major investors are buying Entera Bio stock?

ENTX stock was bought by a variety of institutional investors in the last quarter, including DLD Asset Management LP.

How do I buy shares of Entera Bio?

Shares of ENTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Entera Bio's stock price today?

One share of ENTX stock can currently be purchased for approximately $2.77.

How big of a company is Entera Bio?

Entera Bio has a market capitalization of $31.66 million and generates $500,000.00 in revenue each year. Entera Bio employs 19 workers across the globe.View Additional Information About Entera Bio.

What is Entera Bio's official website?

The official website for Entera Bio is

How can I contact Entera Bio?

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The company can be reached via phone at 972-2532-7151 or via email at [email protected]

MarketBeat Community Rating for Entera Bio (NASDAQ ENTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  250
MarketBeat's community ratings are surveys of what our community members think about Entera Bio and other stocks. Vote "Outperform" if you believe ENTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/26/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel